|Values are valid only on day of printing.|
Medco Health Solutions, Inc, and Mayo Clinic jointly evaluated the medical, clinical and cost-savings potential of genetic testing, while improving patient safety and care, in the Medco-Mayo Warfarin Effectiveness Study (MM-WES).
This national study conducted in the United States, compared patient outcomes when warfarin (a widely used blood thinner) was dosed using pharacogenomic and clinical factors versus just clinical factors.
Medco, Mayo Clinic Study Reveals Using a Simple Genetic Test Reduces
Hospitalization Rates by Nearly a Third for Patients on
Widely Prescribed Blood Thinner
Medco Health Solutions, Inc. and Mayo Clinic Joint Press Release (March 16, 2010)
Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience
Mayo Clinic Proceedings - Thomas Moyer, PhD, December 2009;84(12):1079-1094
Warfarin Sensitivity Genotyping: Why? When? How to Use It to Best Advantage
Mayo Clinic Medical Grand Rounds video (47 minutes) – Robert D. McBane, MD, Thomas Moyer, PhD, and Dennis O'Kane, PhD (March 2010)
Mayo Clinic News Blog
Thomas Moyer, PhD, from Mayo Clinic's Department of Laboratory Medicine and Pathology, offers background on the blood thinner warfarin and why genetic variations in patients affect the dose that will be needed to prevent both blood clots and possible side effects, such as excessive bleeding.
Warfarin: Genotyping and Improving Dosing
Mayo Medical Laboratories Communiqué article (August 2008)
Mayo Validation Support Services
Mayo Validation Support Services (MVSS) assists pharmaceutical, biotechnology and diagnostic companies in the preclinical validation of promising targets, lead compounds, biomarkers and tests. MVSS provided study project management services for the Medco and Mayo Clinic study.
American College of Cardiology
Warfarin Effectiveness Study (MM-WES): Genotyping Reduces Risk of Hospitalization released at annual conference (March 16, 2010)